StreetAlpha.app
Home › Stocks › MNKD

Mannkind Corp (MNKD)

Healthcare
$3.85
▼ −2.53%
LAST CLOSE · NOV 20

MannKind develops and sells inhaled and wearable treatments for diabetes, heart failure and lung conditions. It last closed at $3.85 on Nov 20, down 2.53% on the day. The next earnings report for MNKD is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, MNKD reported EPS of -$0.07 on revenue of $101.9M, with revenue up 24.0% from a year ago. Over its last 8 reports the stock moved an average of 6.2% the session after earnings. Over the last 12 months MNKD insiders bought $259K of stock on the open market and sold $3.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is MNKD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold MNKD.

Key Stats

Last 12 months
Results
Revenue
$413.4M
+31.7% vs a year ago
Net income
−$74.8M
−356.0% vs a year ago
EPS (diluted)
−$0.24
−340.0% vs a year ago
Free cash flow
−$78.4M
−19.0% margin
Valuation
Market cap
$1.2B
321.6M shares
P/E
–
No P/E while losing money
Price to sales
3.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$41.3M
At Sep 30
Debt
$319.4M
At Sep 30
Shareholder equity
−$37.3M
Shares outstanding
321.6M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $75.4M$75.4MFY2021FY2022: $99.8M$99.8MFY2022FY2023: $199.0M$199.0MFY2023FY2024: $285.5M$285.5MFY2024FY2025: $349.0M$349.0MFY2025

From MNKD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.07
Quarter ended Sep 2026
Year ago EPS
$0.03
−333.3% on a GAAP basis
Revenue
$101.9M
+24.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.03Dec '24Mar 2025: $0.04Mar '25Jun 2025: $0.00Jun '25Sep 2025: $0.03Sep '25Dec 2025: -$0.05Dec '25Mar 2026: -$0.05Mar '26Jun 2026: -$0.06Jun '26Sep 2026: -$0.07Sep '26Latest -$0.07
Revenue by quarter
Dec 2024: $76.8MDec '24Mar 2025: $78.4MMar '25Jun 2025: $76.5MJun '25Sep 2025: $82.1MSep '25Dec 2025: $112.0MDec '25Mar 2026: $90.2MMar '26Jun 2026: $109.4MJun '26Sep 2026: $101.9MSep '26Latest $101.9M
How MNKD moved after its last 8 reports
Average move the session after a report ±6.2%
Nov 5, 2026After the close+3.7%
Aug 5, 2026After the close−5.1%
May 6, 2026After the close−0.3%
Feb 26, 2026Time not announced−7.4%
Nov 5, 2025Time not announced+10.6%
Aug 6, 2025Time not announced−13.2%
May 8, 2025Time not announced−4.5%
Feb 26, 2025After the close−4.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on MNKDStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on MNKD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on MNKD

Technical Analysis

MNKD · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend

The stock is 0% above its 20 day and 7% above its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 52). The nearest support is the 20 day average at $3.84, and the nearest resistance the Pivot at $3.92.

Short trendBullish
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 5.3%/day
Key levels
$6.5152 week high+69.1%
$4.01Pivot R1+4.2%
$3.94Swing high (May 29)+2.3%
$3.92Pivot+1.8%
$3.85Last close
$3.8420 day average−0.3%
$3.80100 day average−1.3%
$3.77Swing low (Jun 25)−2.1%
$3.76Pivot S1−2.3%
$3.60200 day average−6.5%
$3.5750 day average−7.3%
$2.2352 week low−42.1%
Indicators
RSI (14)52.14Middle of its rangeNeutral
MACD0.15Below its signal lineBearish
Stochastic56.1Middle of its rangeNeutral
ADX (14)23.2Weak trend
Williams %R-65.3Oversold below −80, overbought above −20Neutral
CCI (20)21.9Oversold below −100, overbought above 100Neutral
Rate of change−1.3%Change over 10 sessionsBearish
ATR (14)$0.20Typical daily range, 5.3% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for MNKD

What happened before

See how MNKD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow MNKD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How MNKD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for MNKDHow many large options trades hit MNKD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

MNKD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼99 buying vs 123 selling
  • ▲Held by funds +3.2 pts
  • ▼Funds holding -11
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding250261−4.2%
In funds' top 10220.0%
Held by funds59.9%56.7%+3.2 pts
New / increased30 / 6949 / 95−31.3%
Reduced / sold out84 / 3962 / 40+20.6%
Put/call ratio0.005.66−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MNKD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

MNKD Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$259K1 buy · 1 insider
Sold$3.2M12 sales · 4 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $2.1M2026-01 sold $298K2026-03 bought $259K2026-05 sold $66K2026-07 sold $311K2026-08 sold $159K2026-09 sold $256KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 25Steven B. BinderDirectorSale plan39,051$3.29$128K
Sep 10Steven B. BinderDirectorSale plan33,558$3.81$128K
Aug 7Steven B. BinderDirectorSale plan39,051$4.06$159K
Jul 17Steven B. BinderDirectorSale plan52,485$4.06$213K
Jul 17David ThomsonEVP Genl Counsel & SecretarySale plan24,109$4.05$98K
May 12David ThomsonEVP Genl Counsel & SecretarySale plan3,033$3.29$10K
Every insider buy and sale for MNKD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See MNKD insider trades →

From SEC Form 4 filings by MNKD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MNKD is in one of them and how their past MNKD trades turned out.

MNKD in the AI portfolios
Loading…

MNKD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MNKD in an article yet. Here's the latest on the wider market.

MNKD in the news

About Mannkind

MannKind is a biopharmaceutical company based in Danbury, Connecticut. Its products include Afrezza, an inhaled mealtime insulin for adults with diabetes, V-Go, a wearable insulin delivery device, and Furoscix, a home-use treatment for fluid buildup linked to heart failure and chronic kidney disease. Its Tyvaso DPI treatment for pulmonary hypertension is sold by partner United Therapeutics, which pays MannKind royalties. The company makes its inhalable powders and inhalers at its Connecticut facility and sells Afrezza in the United States and through partners in other countries.

Headquarters
Danbury, CT
Founded
1991